| SHANGHAI-BENKE-MEDICAL-TECHNOLOGY-CO-LTD |
SHANGHAI-BENKE-MEDICAL-TECHNOLOGY-CO-LTD |
85%
|
to the Company, it is a common practice in the medical device industry for companies to rely on a considerable number of distributors to sell their products. Distributors usually purchase products fr… |
| DIDIY |
DiDi Global Inc. |
72%
|
Reciprocal relationship from DIDIY graph: Reciprocal relationship from WOK graph: sidiaries had a total of 141, 143, and 135 suppliers, respectively. For the fiscal year ended September 30, 2024, the… |
| DIDIY |
DiDi Global Inc. |
72%
|
sidiaries had a total of 141, 143, and 135 suppliers, respectively. For the fiscal year ended September 30, 2024, the top three significant suppliers represented approximately 15%, 10%, and 7% of the… |
| GEMPHARMATECH-CORPORATION |
GEMPHARMATECH-CORPORATION |
62%
|
ice agreement (the “Agreement”) with GemPharmatech Corporation (“GemPharmatech”), a Delaware-based leading contract research organization. Pursuant to the Agreement, Neologics agrees to serve as an i… |
| GROUP-THE-GROUP |
GROUP-THE-GROUP |
62%
|
, and the length of the credit period is dependent on the customer’s creditworthiness and its transaction experience with the Group. The Group makes its judgment taking all of the facts and circumsta… |
| GUANGZHOU-WEILI-MEDICAL-DEVICE-CO-LTD |
GUANGZHOU-WEILI-MEDICAL-DEVICE-CO-LTD |
62%
|
ct to continue to invest in acquiring new patents and technologies that are tailored to the market’s fast-changing requirements. 69 Competition The medical device industry is intensely competitive, s… |
| HANGZHOU-HANSHI-MEDICAL-EQUIPMENT-CO-LTD |
HANGZHOU-HANSHI-MEDICAL-EQUIPMENT-CO-LTD |
62%
|
ei Zhang. In exchange, Work Cayman issued the remainder of its 45 % Ordinary Shares at par value $ 1.00 per share to these strategic investors on the day of its incorporation. ● on March 15, 2022, Wo… |
| HANGZHOU-MEDICAL-TREATMENT-EQUIPMENT-CO-LTD |
HANGZHOU-MEDICAL-TREATMENT-EQUIPMENT-CO-LTD |
62%
|
assure you that the PRC subsidiaries will be able to successfully maintain, or complete any required updating and renewal of, these licenses and permits on a timely basis. See “Item 3. Key Informatio… |
| HANGZHOU-WOLI-MEDICAL-TREATMENT-TECHNOLOGY-CO-LT |
HANGZHOU-WOLI-MEDICAL-TREATMENT-TECHNOLOGY-CO-LT |
62%
|
r using merger accounting as if the Reorganization had been consummated at the beginning of the earliest period presented, and no gain or loss was recognized. All the assets and liabilities of Hangzh… |
| HANGZHOU-YOUSHUNHE-TECHNOLOGY-CO-LTD |
HANGZHOU-YOUSHUNHE-TECHNOLOGY-CO-LTD |
62%
|
r using merger accounting as if the Reorganization had been consummated at the beginning of the earliest period presented, and no gain or loss was recognized. All the assets and liabilities of Hangzh… |
| HENAN-TUOREN-MEDICAL-DEVICE-CO-LTD |
HENAN-TUOREN-MEDICAL-DEVICE-CO-LTD |
62%
|
ct to continue to invest in acquiring new patents and technologies that are tailored to the market’s fast-changing requirements. 69 Competition The medical device industry is intensely competitive, s… |
| HOLDING-COMPANY-STRUCTURE-WORK-MEDICAL-TECHNOLOG |
HOLDING-COMPANY-STRUCTURE-WORK-MEDICAL-TECHNOLOG |
62%
|
e of $864,585, due to the increase in the purchase of raw materials in response to market demand; (d) a decrease in prepaid expenses and other current assets of $1,291,145, which was primarily due to… |
| HUNAN-SAITUMOFEI-MEDICAL-TREATMENT-TECHNOLOGY-CO |
HUNAN-SAITUMOFEI-MEDICAL-TREATMENT-TECHNOLOGY-CO |
62%
|
r using merger accounting as if the Reorganization had been consummated at the beginning of the earliest period presented, and no gain or loss was recognized. All the assets and liabilities of Hangzh… |
| KINGSWOOD-CAPITAL-PARTNERS-LLC |
KINGSWOOD-CAPITAL-PARTNERS-LLC |
62%
|
Item 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Foreign Exchange Risk A substantial majority of our operating activities are denominated in RMB and all of our assets and liabiliti… |
| NEOLOGICS-BIOSCIENCE-INC |
NEOLOGICS-BIOSCIENCE-INC |
62%
|
Neologics Bioscience Inc. (“Neologics”), has entered into a key service agreement (the “Agreement”) with GemPharmatech Corporation (“GemPharmatech”), a Delaware-based leading contract research organi… |
| OPERATING-LEASE-THE-GROUP |
OPERATING-LEASE-THE-GROUP |
62%
|
e of $864,585, due to the increase in the purchase of raw materials in response to market demand; (d) a decrease in prepaid expenses and other current assets of $1,291,145, which was primarily due to… |
| SHANGHAI-CHARTWELL-MEDICAL-DEVICE-CO-LTD |
SHANGHAI-CHARTWELL-MEDICAL-DEVICE-CO-LTD |
62%
|
assure you that the PRC subsidiaries will be able to successfully maintain, or complete any required updating and renewal of, these licenses and permits on a timely basis. See “Item 3. Key Informatio… |
| SHANGHAI-CHUQIANG-MEDICAL-EQUIPMENT-CO-LTD |
SHANGHAI-CHUQIANG-MEDICAL-EQUIPMENT-CO-LTD |
62%
|
r using merger accounting as if the Reorganization had been consummated at the beginning of the earliest period presented, and no gain or loss was recognized. All the assets and liabilities of Hangzh… |
| SHANGHAI-SAITUMOFEI-MEDICAL-TREATMENT-TECHNOLOGY |
SHANGHAI-SAITUMOFEI-MEDICAL-TREATMENT-TECHNOLOGY |
62%
|
r using merger accounting as if the Reorganization had been consummated at the beginning of the earliest period presented, and no gain or loss was recognized. All the assets and liabilities of Hangzh… |
| ZHEJIANG-SUJIA-MEDICAL-DEVICE-CO-LTD |
ZHEJIANG-SUJIA-MEDICAL-DEVICE-CO-LTD |
62%
|
ct to continue to invest in acquiring new patents and technologies that are tailored to the market’s fast-changing requirements. 69 Competition The medical device industry is intensely competitive, s… |
